Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 TrialLonghurst HJ, Smith MD, Yea CM, Audhya PK
EAC 2023
Rationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-SIverson M, Duckworth E, Hansen E, Hampton SL, Smith MD, Audhya PK, Yea CM
C1 Inhibitor Workshop 2023
Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 TrialBernstein JA, Riedl MA, Lumry WR, Audhya PK, Smith MD, Yea CM
AAAAI 2023
A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy VolunteersSmith MD, Iverson M, Hansen E, Audhya PK, Yea CM
AAAAI 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Sebetralstat in Healthy Japanese and White Adults: Results From a Phase 1, Randomized, Double-Blind, Placebo-Controlled TrialIverson M, Jhee S, Hansen E, Duckworth EJ , Hampton SL, Yoon E
WSAAI 2023
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary AngioedemaAygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD
WSAAI 2023
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary AngiodemaDavie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S
PMID: 36251573
Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participantsMutch P, Bashir M, Jung B, Yi P, Iverson M
PMID: 36200371
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 TrialLonghurst HJ, Smith MD, Yea CM, Audhya PK
ASCIA 2022
Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial DesignAygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M
EAACI 2022